Blockchain Registration Transaction Record

Lantern Pharma & Hoth Partner on AI Blood-Brain Barrier Drug Platform

Lantern Pharma partners with Hoth Therapeutics to deploy AI platform PredictBBB.ai™ for neurological drug development. The technology predicts blood-brain barrier penetration with 94% accuracy.

This collaboration represents a breakthrough in neurological drug development that could significantly impact millions of patients suffering from brain-related disorders. The ability to accurately predict which drug candidates can cross the blood-brain barrier addresses one of the most persistent challenges in neuroscience and pharmaceutical research. For patients with conditions like Alzheimer's, Parkinson's, brain tumors, and other neurological diseases, this advancement could mean faster access to effective treatments that were previously impossible to develop. The technology's 94% accuracy rate and potential to reduce development timelines from years to months could revolutionize how we approach neurological drug discovery, potentially bringing life-changing therapies to market more quickly and cost-effectively than ever before.